Patent 7947482 was granted and assigned to Probi AB on May, 2011 by the United States Patent and Trademark Office.
The invention refers to new strains of Bifidobacterium, especially of the species Bifidobacterium infantis, having the ability to survive in the intestinal tract and to produce glutamine and optionally arginine in vivo, as well as to compositions comprising said strains.